Allergy to carbamazepine: parallel in vivo and in vitro detection.
OBJECTIVE
Five to 20% of patients discontinue antiepileptic drug (AED) therapy because of adverse reactions. Careful reintroduction, however, may be considered if true drug allergy can be ruled out. Definitive assessment of such immunologically mediated reactions requires demonstration of either specific antibodies or sensitized lymphocytes.


METHODS
We investigated whether skin patch tests (PTs) and in vitro lymphocyte proliferation assays (LPAs) were suitable for detection of allergy to carbamazepine (CBZ) and the possibly cross-reactive oxcarbazepine (OCBZ). Data of 65 patients displaying a wide range of possibly allergic side effects to CBZ were available for analysis. Data of CBZ users without any side effects and healthy volunteers served as controls. Both PTs and LPAs were done with CBZ, OCBZ and three metabolites [CBZ-10,11-epoxide (CBZ-E), 10-monohydroxy-CBZ (MHD), and 10,11-dihydroxy-CBZ (DIOL)].


RESULTS
Positive PTs with CBZ were seen in 20% and with OCBZ in 14% of the patients. Positive LPA results with CBZ and OCBZ, respectively, were found in 40 and 19%. Both tests were positive in 14 and 7% of the patients. Cross-reactivity to OCBZ was seen in -40% of CBZ-reactive patients in both PTs and LPAs.


CONCLUSIONS
These data illustrate the additional value of LPAs in the detection of CBZ allergy while showing that a major part of side effects to CBZ and OCBZ is not immunologically mediated, according to PTs and LPAs.
Troost
R J
RJ
Department of Immunology, Erasmus University, Rotterdam, The Netherlands.
Van Parys
J A
JA
Hooijkaas
H
H
van Joost
T
T
Benner
R
R
Prens
E P
EP
D000293:Adolescent; D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003429:Cross Reactions; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D010328:Patch Tests
D002220:Carbamazepine; D000078330:Oxcarbazepine